Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: Correlation with haematological parameters

British Journal of Radiology

Volumn 81, Issue 965, 2008, Pages 386-396

  Horger, Marius ^a   Pereira, P ^a   Claussen, C D ^a   Kanz, L ^a   Vonthein, R ^a   Denecke, B ^a   Driessen, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PARAPROTEIN;

ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CANCER PATIENT; CANCER SIZE; CANCER STAGING; CELL INFILTRATION; CLINICAL ARTICLE; FEMALE; HEMATOLOGICAL PARAMETERS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIGHT CHAIN; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; MULTIPLE MYELOMA; OSTEOLYSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEINURIA; RADIATION DOSE; WHOLE BODY CT;

ADULT; AGED; BONE MARROW DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 44349156658     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/21850180     Document Type: Article

References (28)

1. Angtuaco EJC, Fassas ABT, Walker R, Sethi R, Barlogie B. Multiple myeloma: clinical review and diagnsostic imaging. Radiology 2004;231:11-23.
2. Kyle R. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992;6:347-58.
3. Durie BGM, Salmon SE. A clinical staging for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975;36:842-54.
4. Fruehwald FXJ, Tscholakoff D, Schwaighofer B, Wicke L, Neuhold A, Ludwig H, et al. Magnetic resonance imaging of the lower vertebral column in patients with multiple myeloma. Invest Radiol 1988;23:193-9.
5. Lecouvet F, Vande Berg BC, Michaux L, Maldague BE, Jamart J, Ferrant A, et al. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 1998;209:653-60.
6. Mahnken AH, Wildberger JE, Gehbauer G, Schmitz-Rode T, Blaum M, Fabry U, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002;178:1429-36.
7. Rahmouni A, Divine M, Mathieu D, Golli M, Haioun C, Dao T, et al. MR appearance of multiple myeloma of the spine before and after treatment. AJR Am J Roentgenol 1193;160:1053-7.
8. Baur A, Stäbler A, Nagel D, Lamerz R, Bartl R, Hiller E, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95:1334-45.
9. Lecouvet F, Vande Berg B, Malghem J, Maldague B. Magnetic resonance imaging in multiple myeloma. Semin Musculoskelet Radiol 2001;5:43-55.
10. Durie B, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the international myeloma foundation. Hematol J 2003;5:379-98.
11. Baur A, Stäbler R, Bartl R, Lamerz R, Scheidler J, Reiser M. MRI gadolinium enhancement of bone marrow: age related changes in normals and in diffuse neoplastic infiltration. Skeletal Radiol 1997;26:414-8.
12. Lecouvet FE, Melghem J, Michaux L, Maldague B, Ferrant A, Michaux JL, et al. Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey. Br J Haematol 1999;106:35-9.
13. Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
14. Horger M, Claussen CD, Bross-Bach U, Vonthein R, Trabold T, Heuschmid M, et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 2004;54:289-97.
15. Hess T, Egerer G, Kasper B, Rasul KI, Goldschmidt H, Kaufmann GW. Atypical manifestations of multiple myeloma: radiological appearence. Eur J Radiol 2006;58:280-5.
16. Greipp RP, Miguel JS, Durie BGM, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Radiol 2005;15:3412-20.
17. 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002;43:1457-63.
18. Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005;184:1199-204.
19. Strauss LG. Positron emission tomography: current role for diagnosis and therapy monitoring in oncology. Oncologist 1997;2:381-8.
20. Libshitz HI, Malthouse SR, Cunningham D, MacVicar DA, Husband J. Multiple myeloma: appearance at MR imaging. Radiology 1992;182:833-7.
21. Baur-Melnyk A, Buhmann S, Dürr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005;55:56-63.
22. Schreiman JS, McLeod RA, Kyle RA, Beabout JW. Multiple myeloma: evaluation by CT. Radiology 1985;154:483-6.
23. Spjut HJ, Dorfman HD, Fechner RE, et al. Tumors of bone and cartilage. Atlas of tumor pathology. Second series. Fascicle 5. Washington DC: Armed Forces Institute of Pathology; 1971: 201.
24. Kyle RA, Schreiman J, McLeod R, Beabout JW. Computed tomography in diagnosis of multiple myeloma and its variants. Arch Intern Med 1985;145:1451-60.
25. Husband JE, Schwartz LH, Spencer J, Ollivier L, King DM, Johnson R, et al. Evaluation of the response to treatment of solid tumours-a consensus statement of the International Cancer Imaging Society. Br J Cancer 2004;90:2256-60.
26. Fletcher BD, Wall JE, Hanna SL. Effect of hematopoietic growth factors on MR images of bone marrow in children undergoing chemotherapy. Radiology 1993;189:745-51.
27. Vanel D, Gilles M, Cesne AL, Guinebretiere JM. Case report. Red marrow recolonization induced by growth factors mimicking an increase in tumor volume durino preoperative chemotherapy: MR study. J Comput Assist Tomog 1997;21:529-31.
28. Horger M, Kanz L, Denecke B, Vonthein R, Pereira P, Claussen CD, et al. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. Cancer 2007;109:1617-26.